Research on strategic motivation and performance of acquisitions in medical and health field —— A case study of Abiomed and Johnson & Johnson
DOI:
https://doi.org/10.54097/h4py9r79Keywords:
Acquisition; performance research; strategic reasoning.Abstract
The medical and healthcare industries are extremely competitive. By mergers and acquisitions, many businesses grow and accept more market share. Businesses can achieve additional development and increase their profit margins through successful mergers and acquisitions. One well-known company in the medical and health sector is Johnson & Johnson. To examine mergers and acquisitions of businesses in the medical and health sector, this article selects the Johnson & Johnson merger and purchase of Abiomed as a case study. It then analyzes the merger and acquisition through performance research and strategic reasoning. The medical and healthcare industries are extremely competitive. By mergers and acquisitions, many businesses grow and take up more market share. Businesses can achieve additional development and increase their profit margins through successful mergers and acquisitions. One well-known company in the medical and health sector is Johnson & Johnson. To examine acquisitions of businesses in the medical and health sector, this article selects the Johnson & Johnson merger and purchase of Abiomed as a case study. It then analyzes the acquisition through performance research and strategic reasoning.
Downloads
References
[1] Roth, G. A., Johnson, C. O., Abate, K. H., Abd-Allah, F., Ahmed, M., Alam, K., ... & Global Burden of Cardiovascular Diseases Collaboration. (2018). The burden of cardiovascular diseases among US states, 1990-2016. JAMA cardiology, 3(5), 375-389.
[2] Gaziano, T., Reddy, K. S., Paccaud, F., Horton, S., & Chaturvedi, V. Cardiovascular disease. Disease Control Priorities in Develo** Countries. 2nd edition. 2006
[4] Patel, R., Kaki, M., Potluri, V. S., Kahar, P., & Khanna, D. (2022). A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Human vaccines & immunotherapeutics, 18(1), 2002083.
[5] https://www.abiomed.com/en-us
[6] Weber, D. M., Raess, D. H., Henriques, J., & Siess, T. H. O. R. S. T. E. N. Principles of Impella cardiac support. Cardiac Interventions Today, 3-16. 2009
[7] Jett, G. K. ABIOMED BVS 5000: experience and potential advantages. The Annals of thoracic surgery, 61(1), 301-304. 1996
[8] Yao, Y. Analysis of Mergers and Acquisitions (M&A) in medical industry. Finance & Economics, 1(5). 2024
[9] Jake Sargent, Rachel Hooper, Jessica Moore, Sarah Wood, Johnson & Johnson Completes Acquisition of Abiomed, dec-22-22.pdf (q4cdn.com)
[10] Dälken, F. Are porters five competitive forces still applicable? a critical examination concerning the relevance for today’s business (Bachelor's thesis, University of Twente). 2014
[11] Stenbacka, R., & Tombak, M. Make and buy: Balancing bargaining power. Journal of Economic Behavior & Organization, 81(2), 2014, 391-402.
[12] Chae, S., & Heidhues, P. (2004). Buyers' alliances for bargaining power. Journal of economics & management strategy, 13(4), 731-754.
[13] Tesia Williams, Jessica Moore, Johnson & Johnson Reports Q1 2023 Results, 1Q23-Press-Release_Final_with-guidance_with-attachments.pdf (q4cdn.com)
[14] Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., ... & GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. Journal of the American college of cardiology, 2020, 76(25), 2982-3021.
[15] Cho, W., Ke, J. Y. F., & Han, C. An empirical examination of the use of bargaining power and its impacts on supply chain financial performance. Journal of Purchasing and Supply Management, 2019, 25(4), 100550.
[16] Long, H. Accounting Analysis. 2023
[17] Headley, H., Peterkin, L., Nyffeler, R., Wiemers, J., & Birkholtz, B. Johnson & Johnson Strategic Audit. 2023
[18] Alston, K., & Roberts, J. P. Partners in new product development: SC Johnson and the alliance for environmental innovation. Corporate Environmental Strategy, 1999, 6(2), 110-128.
[19] Ross, V., Christian, P., & Menon, A. S. Neurostimulation devices. Medical Technologies to Watch in 2024: Five transformative areas of innovation, 2024, 21.
[20] Lombardino, J. G. A brief history of Pfizer Central Research. Bull. Hist. Chem, 2000, 25(10).
[21] Qian Tongxin. Johnson & Johnson medical strategy adjustment cardiovascular intervention field set off a wave. China Business News, A10.doi : 10.28207/n.cnki.ndycj.2024.001632.3
[22] 2023 Annual Report, jnj4244661-ars.pdf (q4cdn.com)
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
